MUC16 and ovarian carcinoma: Thus, the prevailing view is that ovarian cancer survivors should be ‘informed about the usefulness and drawbacks of CA125 measurements' so they can make an ‘informed choice' about being monitored through the biomarker (Karam and Karlan, 2010; see also Fayed, 2009).